Anti-IL17 antibody Secukinumab therapy is associated with ossification in giant cell tumor of bone: a case report of pathologic similarities and therapeutic potential similar to Denosumab

BACKGROUND: Giant cell tumor of bone is a benign, locally aggressive neoplasm. Surgical resection is the preferred treatment method. However, for cases in which resection poses an increased risk to the patient, denosumab (anti-RANKL monoclonal antibody) is considered. Secukinumab is an anti-IL-17 an...

Descripción completa

Detalles Bibliográficos
Autores principales: Chandler, Andrew, Bartelstein, Meredith K., Fujiwara, Tomohiro, Antonescu, Cristina R., Healey, John H., Vaynrub, Max
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8015053/
https://www.ncbi.nlm.nih.gov/pubmed/33794838
http://dx.doi.org/10.1186/s12891-021-04182-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8015053/
https://www.ncbi.nlm.nih.gov/pubmed/33794838
http://dx.doi.org/10.1186/s12891-021-04182-z

Ejemplares similares